Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Retained Earnings (2016 - 2025)

Catalyst Pharmaceuticals' Retained Earnings history spans 16 years, with the latest figure at $474.2 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 66.29% year-over-year to $474.2 million; the TTM value through Dec 2025 reached $474.2 million, up 66.29%, while the annual FY2025 figure was $474.2 million, 66.29% up from the prior year.
  • Retained Earnings reached $474.2 million in Q4 2025 per CPRX's latest filing, up from $446.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $474.2 million in Q4 2025 to a low of -$32.5 million in Q3 2021.
  • Average Retained Earnings over 5 years is $69.0 million, with a median of $14000.0 recorded in 2023.
  • Peak YoY movement for Retained Earnings: tumbled 502820.72% in 2021, then soared 2036764.29% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$148000.0 in 2021, then soared by 116.22% to $24000.0 in 2022, then tumbled by 41.67% to $14000.0 in 2023, then skyrocketed by 2036764.29% to $285.2 million in 2024, then skyrocketed by 66.29% to $474.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Retained Earnings are $474.2 million (Q4 2025), $446.8 million (Q3 2025), and $31000.0 (Q2 2025).